Adaptimmune Therapeutics plc (473A) — Net Asset Quality Index
Adaptimmune Therapeutics plc (473A) has a Net Asset Quality Index of -54.3% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €130.63 Million minus total liabilities of €201.59 Million yields net assets of €-70.96 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Adaptimmune Therapeutics plc (473A) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Adaptimmune Therapeutics plc Net Asset Quality Index Over Time (2016–2024)
This chart shows how Adaptimmune Therapeutics plc's Net Asset Quality Index has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the index stands at -54.3%, representing net assets of €-70.96 Million against total assets of €130.63 Million EUR. See 473A working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Adaptimmune Therapeutics plc (2016–2024)
The table below presents the year-by-year Net Asset Quality Index for Adaptimmune Therapeutics plc from 2016 to 2024, covering 9 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Adaptimmune Therapeutics plc market cap and net worth.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 4.8% | €11.85 Million | €245.96 Million | €234.11 Million | ▼ -9.2 pp |
| 2023 | 14.0% | €39.51 Million | €282.62 Million | €243.10 Million | ▼ -10.9 pp |
| 2022 | 24.9% | €81.88 Million | €328.92 Million | €247.04 Million | ▼ -19.0 pp |
| 2021 | 43.9% | €205.96 Million | €469.55 Million | €263.58 Million | ▼ -31.8 pp |
| 2020 | 75.6% | €341.23 Million | €451.14 Million | €109.92 Million | ▲ +7.5 pp |
| 2019 | 68.1% | €123.64 Million | €181.54 Million | €57.91 Million | ▼ -21.1 pp |
| 2018 | 89.2% | €246.88 Million | €276.74 Million | €29.85 Million | ▲ +17.0 pp |
| 2017 | 72.2% | €202.98 Million | €281.15 Million | €78.16 Million | ▲ +1.4 pp |
| 2016 | 70.8% | €166.14 Million | €234.51 Million | €68.37 Million | — |